Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Gazprom will not buy out the additional issue of OGK-2

9/7/23 OGKB

Moscow Exchange plans to connect to all DFA issuance platforms

9/6/23 MOEX

Private investor activity in August was a record high

9/6/23 MOEX

Investors will be able to become qualified by passing an exam

9/6/23 MOEX

Moscow Exchange proposed a set of measures to protect minority investors

9/6/23 MOEX

Moscow Exchange will present its development strategy by the end of September

9/6/23 MOEX

Kamaz in 2024 will present a waterbus on a new component base

9/6/23 KMAZ

Alrosa will build an integrated gas treatment unit for Novolenskaya TPP

9/6/23 ALRS

Samaraenergo reported for 6 months of 2023 by IFRS

9/6/23 SAGO

Alice" will speak in Kazakh by the end of the year

9/6/23 YNDX